Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Integra LifeSciences Q4 2025 Earnings Call - Quality and Supply Fixes Drive Cautious 2026 Recovery Plan
Integra closed 2025 having made visible progress on quality, compliance, and supply reliability, but the company is deliberately conservative about near-term growth while remediation and tariff uncert...
- Q4 2025 revenue was $435 million, adjusted EPS $0.83, both above the midpoint of guidance; sequential revenue improved by $33 million versus Q3.
- Full-year 2025 revenue was $1.635 billion, up 1.5% reported but down 0.7% on an organic basis, with Acclarent acquisition a key contributor to reported growth.
- Organic performance was hampered by quality remediation and supply constraints, notably in Tissue Technologies where Q4 revenue fell 12.8% (MediHoney remediation and tough Integra Skin comps were main drivers).
- +12 more takeaways
Hafnia Q4 2025 Earnings Call - Strong quarter and strategic push toward a TORM combination
Hafnia closed 2025 on a strong note, reporting Q4 net profit of $109.7 million and full-year net profit of $339.7 million. The company is returning capital aggressively, declaring an 80% payout for Q4...
- Q4 net profit $109.7 million, full-year 2025 net profit $339.7 million; Q4 was the strongest quarter of 2025 for Hafnia.
- Hafnia acquired 13.97% of TORM from Oaktree and is engaging with stakeholders to explore a potential combination, citing strategic, commercial and financial synergies.
- Dividend policy remains explicit and cash returns are large: 80% payout for Q4 equals $87.7 million, full-year dividends $271.7 million, implied yield about 10% for 2025.
- +13 more takeaways
Playtika Holding Corp Q4 2025 Earnings Call - D2C Hits $1 Billion Run Rate as SuperPlay Rewrites the Mix
Playtika closed 2025 with a clear strategic pivot: direct-to-consumer (D2C) and casual SuperPlay titles are reshaping revenue mix and cash generation, even as GAAP results took a big one-time hit from...
- Q4 2025 revenue was roughly $678.8 million, with Adjusted EBITDA of $201.4 million.
- Direct-to-consumer (D2C) reached a ~$1 billion annual run rate and represented 36.8% of Q4 revenue, a central part of management’s multi-channel strategy.
- Casual games now account for about 74% of Playtika’s revenue, reflecting a multi-year mix shift away from reliance on social casino titles.
- +12 more takeaways
Stellantis Full Year 2025 Earnings Call - Decisive Reset Returned H2 Growth; 2026 Is Year of Execution
Stellantis framed 2025 as a year of reset and paid the near-term cost. The company returned to top-line growth in H2 2025 after product and commercial fixes, but the income statement still shows the d...
- Company view: 2025 was a deliberate reset year, H2 showed return to top-line growth and early benefits from actions taken.
- Full-year results: consolidated shipments 5.5 million units (+1%), net revenues EUR 153 billion (-2%), AOI margin negative 0.5%, industrial free cash flow outflow EUR 4.5 billion.
- H2 improvement: H2 net revenues growth and pricing gains (net pricing +2% in H2 North America) helped drive a sequential recovery; H2 industrial FCF was negative EUR 1.5 billion, a 50% sequential improvement and 73% YoY improvement.
- +15 more takeaways
Cronos Group Q4 2025 Earnings Call - Record 2025, Spinach vape breakout and Netherlands acquisition
Cronos closed 2025 with its strongest year yet, reporting record net revenue, gross profit, and Adjusted EBITDA while growing organically by 25%. The fourth quarter accelerated that momentum, with con...
- Cronos reported a record 2025, growing net revenue organically by 25% year-over-year and posting record full-year gross profit and Adjusted EBITDA.
- Q4 2025 consolidated net revenue was $44.5 million, up 47% year-over-year, driven by higher flower sales in Israel and Canada and stronger Canadian extract sales.
- Spinach was the company standout in Canada, becoming the number 2 overall vape brand in December and the number 1 vape cartridge brand in Q4, led by Cherry Crush and Blueberry Dynamite.
- +11 more takeaways
Dorman Products Fourth Quarter 2025 Earnings Call - Tariff timing to pressure early 2026 margins, but company guides 7%-9% sales growth
Dorman reported a solid 2025 on the top line and margins, but the call read like a company still wrestling with trade policy aftershocks. Full-year sales hit $2.13 billion, up 6%, and adjusted EPS ros...
- 2025 full-year net sales $2.13 billion, up 6% year-over-year; Q4 net sales $538 million, up about 1% versus prior year.
- Adjusted diluted EPS for 2025 was $8.87, a 24% increase year-over-year; Q4 adjusted diluted EPS was $2.17, down 1% versus a very strong Q4 2024.
- Tariffs remain the dominant narrative. Management estimates incremental tariffs reduced 2025 adjusted EPS by approximately $1.25.
- +14 more takeaways
PENN Entertainment Q4 2025 Earnings Call - Rebrand and iCasino Momentum Set Interactive to Break Even in 2026
PENN used Q4 to show that the heavy strategic investments of the last few years are starting to pay off. The U.S. sportsbook rebrand to theScore Bet on December 1 delivered retention and a December po...
- Retail: Q4 retail revenues were $1.4 billion, with retail adjusted EBITDAR of $456.4 million and segment adjusted EBITDAR margin of 32.3%.
- Interactive: Q4 interactive revenues were $398.7 million, including a tax gross up of $182.7 million, and the interactive segment posted an adjusted EBITDA loss of $39.9 million for the quarter.
- Rebrand: PENN rebranded its U.S. sportsbook to theScore Bet on December 1, retaining users through the transition and delivering positive adjusted EBITDA in December.
- +14 more takeaways
Qnity Electronics Q4 2025 Earnings Call - Sustained momentum with conservative 2026 guide, $100M transformation to capture AI-led semiconductor demand
Qnity closed 2025 with steady execution: Q4 net sales of $1.2 billion (up 8% y/y) and full-year net sales of $4.75 billion, delivering 10% organic sales growth and $1.4 billion of adjusted pro forma o...
- Q4 net sales $1.2B, +8% year-over-year; full-year 2025 net sales $4.75B, +10% organic growth.
- Adjusted pro forma operating EBITDA for FY2025 was $1.4B, margin 29.5%; Q4 adjusted pro forma operating EBITDA was $349M and adjusted pro forma EPS was $0.82.
- Segment performance split: Semiconductor Technologies $2.65B in sales, organic growth 8%; Interconnect Solutions $2.1B, organic growth 12% with strong operating leverage.
- +12 more takeaways
Rackspace Technology Q4 2025 Earnings Call - Pivot to Platform Engineering as Backbone for Enterprise AI
Rackspace closed Q4 2025 with revenue of $683 million, beating guidance as public cloud outperformed while private cloud underdelivered due to a slow-ramping large healthcare deployment. Management fr...
- CEO Gajen Kandiah, five months into the role, says the company is pivoting to a platform engineering model, embedding engineers inside customer environments to operationalize AI, not just advise or resell infrastructure.
- Rackspace positions itself as the infrastructure and operations backbone for enterprise AI, with private cloud and governed environments central for data-sensitive and regulated workloads.
- Q4 GAAP revenue was $683 million, with private cloud at $241 million (below guidance) and public cloud at $442 million (above guidance).
- +13 more takeaways
Park Dental Partners Q4 2025 Earnings Call - IPO Completed, Specialty Growth and Land-and-Expand M&A Take Center Stage
Park Dental Partners closed 2025 with record revenue and adjusted EBITDA, an early-December IPO, and a clear land-and-expand playbook aimed at growing the number of doctors across its footprint. Q4 re...
- Q4 2025 revenue $61.2 million, up 7.5% year-over-year; full-year 2025 revenue $244.5 million, up 6.4%.
- Same-practice revenue growth was 6.3% in Q4 and 5.8% for full-year 2025; normalizing for one fewer operating day, full-year same-practice growth would be 6.9%.
- Multi-specialty and specialty services are outpacing general dentistry, with specialty practice revenue up 11.0% for the year to $65.5 million, and Q4 multi-specialty revenue up 11.3% to $16.5 million.
- +11 more takeaways